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oping a bridging therapy suitable for treating large numbers of
people exposed to high doses of ionizing irradiation. These pre-
clinical experiments indicate that allogeneic MP generated from
puriﬁed HSC by ex vivo expansion can function as a bridging
therapy during hematopoietic recovery following high-dose radi-
ation.
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KERATINOCYTE GROWTH FACTOR (KGF) IS REQUIRED FOR POST-
NATAL THYMIC REGENERATION
Alpdogan, O.1; Hubbard, V.M.1; Muriglan, S.J.1; Goldberg, G.L.2;
Kochman, A.A.1; Eng, J.M.1; Smith, O.M.1; Boyd, R.L.2; van den
Brink, M.R.M.1 1. Memorial Sloan-Kettering Cancer Center, New
York, NY; 2. Monash University, Melbourne, Victoria, Australia.
KGF is a ﬁbroblast growth factor family member (FGF-7) that
mediates epithelial cell proliferation and differentiation in a variety
of tissues. Recent pre-clinical studies have demonstrated that KGF
administration (before conditioning) to the recipients of allogeneic
bone marrow transplantation (BMT) can enhance T cell and thy-
mic reconstitution. Therefore, we studied the role of KGF on T
cell development by using KGF (/) mice in experimental mu-
rine models. Phenotypic analysis of KGF (/) mice at varying
ages (6–44 weeks) demonstrated that the bone marrow, thymus
and lymph node cellularity and the cell distribution, as well as
thymic stromal cell composition among KGF (/), wild type
(WT) and KGF (/) mice were similar. However, splenic cellu-
larity and splenic T cell numbers were slightly lower than WT and
KGF (/) controls. More importantly, KGF (/) mice had a
greater than six fold decrease in thymic cellularity after sublethal
irradiation (450 cGy), while erythroid, myeloid and platelet recov-
ery were intact. In our preliminary experiments the analysis of
thymic stroma revealed that ﬁbroblast numbers were decreased in
KGF (/) compared to controls following sublethal irradiation.
We used bone marrow transplantation models to assess the relative
contribution of KGF produced by thymocytes or thymic stromal
cells during thymic regeneration after irradiation. T cell reconsti-
tution was impaired in syngeneic or allogeneic KGF (/) BMT
recipients in comparison to KGF (/) controls but there was no
difference in the distribution of thymocyte subsets or splenic T cell
content. The recipients of KGF (/) bone marrow had decreased
thymic and splenic cellularity after allogeneic BMT. These data
demonstrate that both donor and host derived KGF play a role in
thymic regeneration. Finally, rhKGF (palifermin) administration
to young and old mice (10 month old) enhanced thymopoiesis
when analyzed 28 days after rhKGF (palifermin) administration.
Pre-BMT rhKGF (palifermin) administration to the recipients of
syngeneic and allogeneic BMT also resulted in a 2–6 fold increase
in thymic cellularity compared to the control group. We conclude
that KGF produced by both thymocytes and thymic stromal cells
is not required for pre- and post-natal thymic development, but
plays a role in post-natal thymic stroma regeneration after irradi-
ation. These data support the potential use of KGF to protect or
restore thymic damage after chemo/radiotherapy.
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IN VIVO DUAL MODALITY CONTEMPORANEOUS IMAGING OF DIFFER-
ENT TUMOR REACTIVE T-CELL SUBPOPULATIONS
Doubrovin, M.M.; Doubrovina, E.S.; Cai, S.; Blasberg, R.G.; O’Reilly,
R.J. Memorial Sloan-Kettering Cancer Center, New York, NY.
Background: Identiﬁcation of the in vivo functions of T-cell
subpopulations in vivo is critical for understanding their interac-
tions in the course of adoptive immune cell therapy. The quanti-
tation of T-cell subpopulations in tissues would also allow for the
assessment of the proliferation potential of these cells. Previously,
we have used various applications of HSV1-tk PET and ﬁreﬂy
Luciferase reporter gene imaging for the generation of cell traf-
ﬁcking images. We have combined these two imaging options to
assess CD4 and CD8 T-cell populations and to correlate cell
numbers and image intensity using microPET and bioluminescent
imaging (BLI). Methods: Cytotoxic T-lymphocytes stably trans-
duced with reporter genes (CTL-TGN or CTL-FLucN) were
administered to NOD-SCID mice bearing previously established
subcutaneous EBV-BLCL xenografts in a dose range from 104 to
107 cells, locally. In vivo imaging of these T-cells either prelabeled
in vitro with [18F]FEAU and D-Luciferine or in vivo by intravenous
infusion of the same probes with microPET and BLI was per-
formed 4 hours after CTL injection. T-cells in post mortem tissue
samples were quantitated by FACS. The radioactivity was also
measured in these samples using gamma-counter. Total activity
obtained from 3-dimensional ROIs for microPET and total pho-
ton ﬂux measured in 2D-ROIs for BLI were used to draw dose-
calibration curves. Results: The values of T-cell retention in
tumor following a direct injection obtained for ex vivo labeled cells
were applied for correction of in vivo labeling results. For both ex
vivo and in vivo labeled T-cells, close correlations between CD8
CTL-TGN number and accumulated radioactivity (nCi/cc for
MicroPET) and between CD4 CTL-FLucN number and BLI
signal intensity expressed as a total photon ﬂux (photon/sec for
BLI) were observed. The limits of sensitivity for both BLI and
MicroPET imaging appeared to be comparable at a depth in tissue
of 7–10 mm (depth of CTL administration), approximating 105
cells. The correlations calculated between the number of CTLs
(dose) and signal intensity were used to build a scale for the
assessment of the cell number and concentration in tissues. Con-
clusions:Dual modality imaging can be used for contemporaneous
quantitative imaging of different T-cell subpopulations after adop-
tive cell therapy using noninvasive in vivo reporter gene-based
imaging techniques, such as MicroPET and BLI.
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ELIMINATION OF ALLOREACTIVE T LYMPHOCYTES USING PHOTODY-
NAMIC THERAPY PREVENTS THE DEVELOPMENT OF GVHD AND PRO-
MOTES B AND T CELL RECONSTITUTION AFTER MHC-MISMATCHED
TRANSPLANTATION
Sidi Boumedine, R.1; Krosl, G.1; Vaillancourt, M.2; Perreault, C.1; Roy,
D.C.1 1. Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 2.
Celmed BioSciences, Montreal, QC, Canada.
Previous studies have demonstrated that photodynamic therapy
can be used to eliminate alloreactive T cells and preserve graft-
versus-leukemia activity in the context of major histocompatibility
complex (MHC) mismatched stem cell transplantation (SCT).
However, the speciﬁcity of the T cell activation process and the
capacity of PDT to promote rapid immune reconstitution has not
been evaluated extensively. The purpose of this study was to de-
termine the capacity of PDT to speciﬁcally target antigen-primed
T lymphocytes and to promote B and T cell post-transplant re-
covery. C57BL/6 donor (B6; H-2b) spleen cells were ﬁrst activated
against C3H/HeJ (C3H; H-2k) host spleen cells in a one-way
mixed lymphocyte culture and then exposed to photodynamic
treatment (PDT) using dibromorhodamine methyl ester
(TH9402) as photosensitizer. Activated (CD25) T cells retained
greater concentrations of the photosensitizer and were preferen-
tially eliminated over resting lymphocytes. When lethally irradi-
ated C3H mice were transplanted with B6 bone marrow cells
supplemented with B6 spleen cells activated against C3H targets,
they rapidly succumbed to acute GVHD (within 10–47 days). In
contrast, when donor (B6) T cells were activated against C3H cells
and then exposed to PDT, 80% of C3H recipients survived (100
days) (p
0.0001). Interestingly, PDT also abrogated (100% sur-
vival) the lethal effect of the same grafts on B10BR (H-2k) recip-
ients (p
0.0001), conﬁrming the importance of the activation step
and the speciﬁcity of the PDT process for anti-H-2k primed cells.
Additionally, transplantation of PDT treated B6 T cells induced
lethal GVHD in histo-incompatible Balb/c mice (H-2d), suggest-
ing that PDT spared resting T lymphocytes for anti-non-host
reactivity. Analysis of immune recovery at day 100, evaluating T
and B cell populations in thymus and spleen, activated T cells
components (CD44, CD62L, CD69), proliferative responses (anti-
CD3 and conA), and V-repertoire indicated that T and B cell
reconstitution in MHC-mismatched mice transplanted with
primed cells exposed to PDT was similar to that of mice trans-
planted with treated or control autologous cells, demonstrating
that immune cells were preserved and functional. These results
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emphasize the importance of antigen-speciﬁc activation in the
selectivity of PDT for alloreactive T cells. Preservation of func-
tional T and B cells post-transplant should translate into protec-
tion against infectious agents and tumor cells.
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COMPLETE CHIMERISM FOLLOWING THE USE OF ANTI-CD33 ANTI-
BODY IN A CHILD WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA
(ALL) AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION (allo
BMT)
Odone-Filho, V.; Carvalho, A.; Ramos, R.R.; Conchon, M.; Cristofani,
L.M. Hospital Sirio Libanes, Sao Paulo, SP, Brazil.
The monoclonal anti-CD33 antibody (gemtuzumab ozogamicin:
GO) represents a therapeutic option for leukemic patients with
CD33-positive disease. Few reports relate its action in patients
with ALL who anomalously express CD33. We here report
GDRT, WM, diagnosed at the age of 4 years as having standard-
risk ALL, whose immunophenotypic expression included: CD34,
HLA-DR, TdT, CD19, CD79a, CD10 and also ectopic presence
of the myeloid antigens CD13 and CD33, treated as per the
Brazilian Cooperative Protocol-93, including: VCR, DEXA,
DAUNO, ASP and ARA-C as induction, high-dose MTX as in-
tensiﬁcation, maintenance with 6-MP, regular and high-dose
MTX and prophylactic intrathecal triple drugs (MADIT: MTX 
ARA-C  DEXA). Unsuccessful reinduction trials elicited by a
marrow recurrence after 12 months in remission were followed by
an allo-BMT, with active disease, the source of cells being the
cord-blood of his HLA-compatible sister. He did achieve a com-
plete engraftment, with normal XX marrow cells, which unfortu-
nately lasted less than 4 months. He was then referred with fully
active disease, over 60,000 blast cells/cu. mm., XX/XY chimera,
with the same initial immunophenotypic expression, hepatospleno-
megaly and adenomegaly, normal CSF and sepsis. Reinduction was
attempted with 8 cycles of VM-26 and ARA-C in 4 weeks followed
by TOPO and ETO, besides MADIT. Although there had been
disappearance of organomegaly and peripheral blast cells after the
3rd VM-26/ARA-C cycle, the marrow remained an M3 one even
13 days after TOPO/ETO exposure. Considering his anomalous
CD33 expression, GO, 3 mg/sq. m., 1-hour iv infusion was then
given. Marrow aplasia was veriﬁed after 7 days and an M1 marrow,
fully XX, was seen after 18 days. Maintenance plans included
monthly cycles of GO, as above, plus MADIT. Marrow sample
obtained at the 8th week after documented remission revealed
again blast cells, whose immunophenotypic expression continued
being the same, except for CD33 negativity. At the time of this
report the child continued being followed as outpatient, with
clearly progressive disease, however receiving only transfusional
support, with no additional therapeutic attempts. Interestingly, his
peripheral blood cells continued mostly being XX ones. GO was
capable of reproducing in a child with ALL and anomalous CD33
expression a complete chimera anteriorly obtained after an allo-
BMT. This might be an option for non-ablative procedures with
stem-cell reinfusion support.
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DEVELOPEMENT OF CHRONIC GVH IS THE STRONGEST PREDICTOR OF
SURVIVAL IN PATIENTS WITH POOR-RISK AML IN REMISSION AFTER
RELATED OR UNRELATED SCT
Fibich, C.1; Luiders, J.2; Douglas, S.2; Robert, T.A.2; Loree, L.2; Chris-
topher, B.2; Assan, C.2; James, R.A.2 1. Department of Hematology/
Oncology, Martin-Luther University, Halle/Saale, Germany; 2. Alberta
BMT Program, Calgary, AB, Canada.
High risk AML by clinical criteria, deﬁned as relapsed or refrac-
tory disease, primary induction-therapy failure, secondary AML or
advanced disease beyond 1st CR has a dismal outcome with all
current therapies. We analysed the inﬂuence of transplant-related
factors and GvHD on the outcome of adult pts with HR-AML who
underwent an allogeneic SCT in the Alberta Transplant Program.
Patients and methods: 105 adult pt median age 42, range 20 to 65y
were transplanted between 5/88 and 7/02. 71 pt received SCT
from related, 34 from matched unrelated donors. Indications for
allo-SCT were: 71 AML, 24 in 2nd CR, 18 refractory relapse, 15
primary induction failure and 14 untreated relapse. 34 pt had
secondary AML, either untreated (N26), refractory (N5) or
relapsed (N3). Conditioning-regimen used were: BuCy N43 (6
pt with ATG), CyTBI N17 (5 pt with ATG), FluBuATG N34,
VP16/TBI, N8, other N3. 62 pt received ATG (Sangstat,
Fresno, USA) and 31 pt TBI. Cytogenetic results were available for
23 adult pt at relapse or pre-BMT and for 25 pt at initial diagnosis.
Of these 3 were favorable (inv16, t8/21), 6 were normal karyotype,
and 8 other single translocations, and 29 were either complex
abnormal karyotype or high risk chromosomal aberrations (del 5q-,
del7). 3y OAS survival for all adult pt was 28% (95% CI: 20.03–
37.54%). No signiﬁcant differences in survival were found for
age-groups, cytogenetic risk-factors, MDS/AML vs AML, pres-
ence of aGvH I°. A trend for improved survival was found for pt
receiving TBI-containing regimen when compared to BuCY
(p0.064). The use of ATG in conditioning did not improve 100
d-OAS (no ATG 68.%, vs ATG 73%). Occurrence of cGvH
resulted in a highly signiﬁcant survival difference in favor of pts
with cGvH with a median survival of 760 vs 230 d (p0.002, HR
2.3) and a 3 y OAS of 47 vs 18% (p
0.01%). Chemotherapy-
intensity or donor-type did not signiﬁcantly inﬂuence outcome in
this poor-risk cohort. The only factor with highly signiﬁcant effect
on survival (p0.003) was the presence of chronic GvH suggesting
a graft vs leukemia effect requiring clinically evident GvH. The
beneﬁcial effect of ATG on early mortality that has been shown in
lower-risk pt-groups was not reproducible in this cohort possibly
due to the high early relapse rate (data not shown).
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ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID
LEUKAEMIA: EXPERIENCE AT ARMED FORCES BONE MARROW TRANS-
PLANT CENTRE-PAKISTAN
Raza, S.; Hashmi, K.U.; Khattak, B.K.; Ahmed, P.; Hussain, I. Armed
Forces Bone Marrow Transplant Center, Rawalpindi, Punjab, Pakistan.
Objective: To evaluate the role and outcome of allogeneic stem
cell transplantation in chronic myeloid leukaemia in our popula-
tion. Methods: Cases suffering from chronic myeloid leukaemia
less than 50 years of age and having HLA matched sibling donor
received allogeneic stem cell transplantation. Conditioning was
done with busulphan 16 mg/kg plus cyclophosphamide 200 mg/kg
(Big Bu/Cy) or busulphan 16 mg/kg plus cyclophosphamide 120
mg/kg (Mini Bu/Cy), GVHD prophylaxis was given with Cyclo-
sporin (CSA) alone, or CSA plus Prednisolone with or without
short course of methotrexate. Patients received PBSC or bone
marrow alone or both. G-CSF was administered either on day 5
or 8 till ANC recovery. Engraftment was deﬁned as achievement
of neutrophil count of 0.5  109/l on 3 consecutive days. Pa-
tient’s engraftment and disease status were assessed at day 21, day
100 and thereafter every three months. Results: Since 5 April
2002 a total of 20 patients of chronic myeloid leukaemia underwent
allogeneic stem cell transplantation. Seventeen were male and 3
female. Median age of the patients was 29 years (range 7–50). 16
cases received PBSC, 1 bone marrow and 3 both. Mean mononu-
clear cell dose was 4.9  108/kg. Median time to neutrophil
recovery was 11.7 days (range 9–14). Neutropenic fever was seen in
80% cases, with mean duration of fever being 6.07 days. In ma-
jority no focus of infection was found. However cultures were
positive in 30% (n6) cases. Various isolates included gram-neg-
ative rods (n3); staphylococcus (n2) and fungi (n1) The com-
mon post engraftment infections were due to gram-negative rods,
tuberculosis, aspergillus, and herpes zoster. Other post-BMT com-
plications included acute GVHD 40%, chronic GVHD 15% and
hemorrhagic cystitis 15%. There were 4 (20%) deaths while in one
patient disease relapsed. Cause of death was septicaemia (n2),
DIC (n1) and disseminated aspergillosis (n1). The overall and
disease free survival (DFS) is 80% and 75% respectively. Mean
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